Prostate cancer breakthrough? 5,500 men to get tumor profiling in huge swedish study

NCT ID NCT06687421

Recruiting now Knowledge-focused Sponsor: Andreas Josefsson Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will enroll 5,500 men with high-risk prostate cancer to analyze their tumors at the molecular level. Researchers hope to find biomarkers that predict which treatments work best. Participants will receive standard care, and the study will not test any new drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors choose the best treatment for each patient based on their tumor's genetic profile.
What could go wrong: This is an observational study, not a treatment trial. It may not directly improve outcomes, and biomarker findings may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Urology, Umeå University Hospital, Region Västerbotten
RECRUITING

Umeå, 901 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.